Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anacetrapib - Merck

Next Previous
Drug Profile

Anacetrapib - Merck

Alternative Names: Anacetrapib; MK-0859

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; University of Oxford
  • Class Antihyperlipidaemics; Oxazolidinones; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 01 Aug 2018 Discontinued - Phase-II for Hyperlipoproteinaemia type IIa (Adjunctive treatment, Monotherapy) in USA (PO)
  • 01 Aug 2018 Discontinued - Phase-III for Atherosclerosis (Adjunctive treatment) in Canada, Italy, Finland, Denmark, Sweden, United Kingdom, Germany, Austria, Spain, USA, Russia, Norway, New Zealand, Mexico, Malaysia, Israel, Australia, Netherlands, France, Hungary, China (PO)
  • 01 Aug 2018 Discontinued - Phase-III for Hypercholesterolaemia (Adjunctive treatment) in Spain, Slovakia, Romania, Poland, Israel, Canada, Mexico, Taiwan, Russia, South Korea, Turkey, Bulgaria, Puerto Rico, Hungary, Germany, United Kingdom, Netherlands, USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top